Here are the 10-K annual reports from Inhibitor Theraptics Inc (INTI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTI filings page.
Inhibitor Therapeutics, Inc. is a pre‑revenue pharmaceutical development company focused on repurposing the antifungal itraconazole to treat basal cell carcinoma nevus syndrome (Gorlin Syndrome). Its lead evidence comes from the HP2001 Phase IIb study in 38 patients with 477 baseline lesions, where per‑lesion objective response was reported at 57.7% and patient‑level disease control at 97.4%.
The company has an FDA Type C meeting granted for its BCCNS program, with written responses expected in May 2026, and holds orphan‑drug designation for itraconazole in this indication. It has engaged Avior Bio to create a proprietary micronized/amorphous itraconazole formulation and licenses angiogenesis‑related IP from Johns Hopkins, aiming to build layered exclusivity.
INTI has minimal operations, only eight employees, no commercial products and no current revenue. It depends on new capital and potential strategic transactions, including a February 2026 securities purchase agreement for $3 million plus warrant funding that is not assured to close. The filing highlights substantial risks: early‑stage clinical status, regulatory uncertainty around its proposed per‑lesion endpoint strategy and 505(b)(2) path, reliance on a small leadership team, intense competition, and a thin, volatile OTCQB trading market. Management acknowledges significant doubt about the ability to continue as a going concern without additional financing or deals.